Insider Shareholders with Direct Ownership of Cytom X Therapeutics, Inc. (CTMX)
This section provides a comprehensive overview of the insiders with direct ownership of Cytom X Therapeutics, Inc. (CTMX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
CytomX Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 1,460,317 | 281,972 | 1,089,684 $2.59 Million | 27 |
Jun 16, 2025
Reduced 4.85%
|
|
|
Marcia Belvin
SVP, Chief Scientific Officer |
245,000 | 58,568 | 272,252 $647,959 | 13 |
Jun 16, 2025
Reduced 4.85%
|
|
Christopher Ogden
Chief Financial Officer |
235,250 | 28,267 | 226,271 $538,524 | 14 |
Jun 16, 2025
Reduced 4.48%
|
|
Yu Waye Chu
Chief Medical Officer |
139,750 | 4,025 | 135,725 $323,025 | 3 |
Mar 18, 2025
Reduced 2.88%
|
|
Lloyd A Rowland
General Counsel |
125,000 | 36,854 | 120,594 $287,013 | 14 |
Mar 18, 2025
Reduced 7.8%
|
|
Jeffrey B Landau
Chief Business Officer |
115,000 | 24,622 | 119,056 $283,353 | 12 |
Aug 20, 2024
Reduced 3.39%
|
|
Amy C. Peterson
EVP, Chief Development Officer |
66,421 | 11,720 | 58,433 $139,070 | 6 |
Mar 16, 2023
Reduced 6.79%
|
|
Carlos Campoy
Chief Financial Officer |
43,921 | 5,697 | 38,224 $90,973 | 6 |
Mar 16, 2023
Reduced 4.37%
|
|
Alison L. Hannah
Chief Medical Officer |
37,500 | 5,602 | 31,898 $75,917 | 3 |
Jul 20, 2022
Reduced 14.94%
|
| 5,000 | 0 | 5,142 $12,237 | 1 |
Mar 29, 2023
Added 49.3%
|